Bringing the antimicrobial peptides, AMPs, in pharmaceutical business
was a long process with many technical hurdles after their discovery
more than 30 years ago. Structure, classification and mode of action of
the AMPs as well as the selection of AMPs for clinical use are
discussed. The preclinical and clinical trial results in phase 1 and
phase 2 studies are discussed for 9 AMPS. These results are encouraging
for the future of the AMPs as alternative antibiotics. Antimicrobial peptides (AMPs) are short #proteins with antimicrobial
activity. A large portion of known AMPs originate from insects. AMPs
from insects represent a potential source of #alternative antibiotics in
the face of rising #antibiotic resistance. AMPs can act against bacteria,
viruses, fungi or parasites. In insects they contribute to host innate
#immunity [1-4]. The first AMP was extracted in 1980 from the pupae of
the giant silk moths and its bactericidal properties were demonstrated
for the first time [5]. Now more than 1500 AMPs have been identified in
different organisms including plants, fungi, bacteria and animals.
Insects are the primary source of AMPs. In traditional Chinese medicine
over 1700 medicines have been produced from circa 300 insect species
[6]. Difficulties in species identification, drug toxicity, development
costs and large scale production slow the development of insect products
into potential modern #medicines [7].
For more articles on BJSTR Journal please click on https://biomedres.us/
For more Medical Genetics Articles on BJSTR
The Antimicrobial Peptides: Ready for Clinical Trials? by Michael AB Naafs in BJSTR
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.